Global Research & Development
Astellas Pharma Global Development Europe (APGD-EU) stands at the leading edge of science and technology. Our R&D strategy focuses on the acceleration and commercialisation of new drugs by concentrating resources on promising projects within clearly defined therapeutic areas.
APGD-EU assumes global responsibility for R&D development in:
- Diabetes/Metabolism/Kidney/Cardiovascular Disease
- Pain Management
APGD-EU also supports global R&D development efforts in the therapeutic areas (TAs) of:
- Inflammation/Immunology (including Gastrointestinal Diseases)
- Infectious Diseases
Worldwide, Astellas has 30 major projects in Phase 3 or pending approval, and more than 50 projects in early-phase clinical development.
We aim to be category leaders within focused therapeutic areas in order to improve the quality of life for patients, their families, and the caregivers who serve them.
Drug discovery and development process
|Discovery||Exploratory Development||Full Development||Post-Approval|
|Find the candidate to best test the hypothesis||Test the candidate for its non-clinical and clinical safety, toleration, PK/PD and pharmacological attributes vs the discovery hypothesis||Develop the candidate into a drug by confirming its clinical attributes and safety in the treatment of specific diseases, conditions, or indications||Continue to develop the candidate post-approval; develop a risk management plan; fulfil all legal obligations of the Marketing Authorisation Holder for registered products|